Skip to main content

Table 1 Baseline socio-demographics of participants

From: Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial

Characteristics

Arm 1:

HCQ + SOC

Arm 2:

SOC alone

Total

Total randomized and analyzed

55

50

105

Age in years

   

Median (IQR)

30 (26–44)

32 (27–42)

32 (27–43)

Range

18–64

20–59

18–64

Age categories, n (%)

   

18–34

29 (52.7)

28 (56.0)

57 (54.3)

35–59

25 (45.5)

22 (44.0)

47 (44.8)

 ≥ 60

1 (1.8)

0

1 (0.9)

Sex, n (%)

   

Male

39 (70.9)

37 (74.0)

76 (72.4)

Female

16 (29.1)

13 (26.0)

29 (27.6)

Baseline SARS COV-2 CT-valuesa

   

Number of observations

17

17

34

Mean (SD)

19.0 (5.1)

18.9 (4.9)

18.9 (4.9)

Median (IQR)

18.8 (16.1–23.0)

19.9 (14.8–22.4)

19.6 (14.8–23.0)

Range (minimum–maximum)

9.6–27.1

9.6–25.5

9.6–27.1

Comorbidity, n (%)

   

High blood pressureb

2 (3.6)

1 (2.1)

3 (2.9)

Heart disease

1 (1.8)

0

1 (0.9)

Diabetesb

2 (3.5)

1 (2.0)

3 (2.8)

Cigarette smokingb

2 (3.6)

0

2 (1.9)

Alcohol dependencyb

7 (12.3)

6 (12.5)

13 (12.4)

HIV positiveb

3 (5.4)

2 (4.1)

5 (4.8)

  1. HCQ hydroxychloroquine, SOC standard of care, SD standard deviation, IQR Inter-quartile range
  2. aThe baseline SARS COV-2 CT-values were defined as the CT-values measured at patient’s enrolment. However, some participants had missing CT values at enrolment because majority of participants reported 4 days after their first positive PCR tests, and the repeat PCR test at enrolment for most of them was negative, as highlighted in this table. Only positive PCR tests could have SARS COV-2 CT-values
  3. bMissing values: High blood pressure (n = 2), Heart disease (n = 1), Diabetes (n = 1), Cigarette smoking (n = 2), Alcohol dependency (n = 2), HIV status (n = 1), History of allergies (n = 1), Medication before admission (n = 1)